(Sharecast News) - Ixico has secured two new clinical trial contracts in neurological disorders with a combined value of about £1.3m, it announced on Friday, extending its presence in both Alzheimer's disease and rare central nervous system conditions.
The AIM-traded firm said the first agreement, with an unnamed major pharmaceutical company,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE